Alexion and Affibody announce partnership to co-develop Anti-FcRn Affibody® molecule
Alexion Pharmaceuticals, announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor. March 20, 2019